You are now leaving our web site.
The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.
ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.
Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers